Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
0(0%)
Results Posted
50%(4 trials)
Terminated
1(8%)

Phase Distribution

Ph phase_2
5
42%
Ph phase_3
1
8%
Ph phase_1
4
33%
Ph phase_4
1
8%
Ph early_phase_1
1
8%

Phase Distribution

5

Early Stage

5

Mid Stage

2

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
4(33.3%)
Phase 2Efficacy & side effects
5(41.7%)
Phase 3Large-scale testing
1(8.3%)
Phase 4Post-market surveillance
1(8.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

72.7%

8 of 11 finished

Non-Completion Rate

27.3%

3 ended early

Currently Active

0

trials recruiting

Total Trials

12

all time

Status Distribution
Completed(8)
Terminated(3)
Other(1)

Detailed Status

Completed8
Withdrawn2
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
12
Active
0
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 14 (33.3%)
Phase 25 (41.7%)
Phase 31 (8.3%)
Phase 41 (8.3%)

Trials by Status

completed867%
terminated18%
unknown18%
withdrawn217%

Recent Activity

0 active trials
Showing 5 of 12
completedphase_2

Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia

NCT07210450
completedphase_1

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

NCT04634539
completedphase_1

L-glutamine Treatment in Patients With Diverticulosis

NCT05106101
completedphase_4

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

NCT04684381
completedphase_2

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

NCT01048905
View all 12 trials

Clinical Trials (12)

Showing 12 of 12 trials
NCT07210450Phase 2

Effect of L-Glutamine on Pulmonary Artery Pressure in Patients With Non-Transfusion-Dependent Thalassemia

Completed
NCT04634539Phase 1

Trial of First-line L-glutamine With Gemcitabine and Nab-paclitaxel in Advanced Pancreatic Cancer

Completed
NCT05106101Phase 1

L-glutamine Treatment in Patients With Diverticulosis

Completed
NCT04684381Phase 4

Pharmacokinetics and Safety of Endari (L-glutamine) in Sickle Cell Disease Patients

Completed
NCT01048905Phase 2

Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension

Completed
NCT00586209Phase 2

L-Glutamine Therapy for Sickle Cell Anemia

Terminated
NCT00125788Phase 2

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

Completed
NCT01179217Phase 3

A Phase III Safety and Efficacy Study of L-Glutamine to Treat Sickle Cell Disease or Sickle βo-thalassemia

Completed
NCT04019769Early Phase 1

Glutamine Supplementation in People With Immune Dysregulation

Withdrawn
NCT03947879Phase 1

The Effect of Pharmaceutical Grade L-glutamine (Endari) on Glycemic Control in Patients With Diabetes Mellitus Type II

Unknown
NCT02215083Phase 1

L-glutamine Supplementation to Alleviate Symptoms of Taxane-Induced Neuropathy in Patients With Breast Cancer

Withdrawn
NCT00296621Phase 2

Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy

Completed

All 12 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
12